Answers are grounded in this paper and cite their sources.
Recent population data suggest independence of the genetic polymorphisms in mephenytoin and sparteine/debrisoquine oxidation. We used human liver preparations to test whether mephenytoin competes with sparteine for binding to the genetically variable cytochrome P-450, which mediates metabolism of both sparteine and debrisoquine. Mephenytoin failed to inhibit in vitro sparteine oxidation. This provides biochemical evidence that the polymorphism of sparteine/debrisoquine metabolism is not related to that of mephenytoin.
No takes yet. Share an insight, caveat, or question.
Jurima et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: